PMID- 28738783
OWN - NLM
STAT- MEDLINE
DCOM- 20180108
LR  - 20220408
IS  - 1471-2261 (Electronic)
IS  - 1471-2261 (Linking)
VI  - 17
IP  - 1
DP  - 2017 Jul 24
TI  - Efficacy of coenzyme Q10 in patients with cardiac failure: a meta-analysis of 
      clinical trials.
PG  - 196
LID - 10.1186/s12872-017-0628-9 [doi]
LID - 196
AB  - BACKGROUND: The therapeutic efficacy of coenzyme Q10 on patients with cardiac 
      failure remains controversial. We pooled previous clinical studies to re-evaluate 
      the efficacy of coenzyme Q10 in patients with cardiac failure. METHODS: We 
      searched PubMed, Cochrane Library, EMBASE, and Clinical Trials.gov databases for 
      controlled trials. The endpoints were death, left heart ejection fraction, 
      exercise capacity, and New York Heart Association (NYHA) cardiac function 
      classification after treatment. The pooled risk ratios (RRs) and standardized 
      mean difference (SMD) were used to assess the efficacy of coenzyme Q10. RESULTS: 
      A total of 14 RCTs with 2149 patients met the inclusion criteria and were 
      included in the analysis. Coenzyme Q10 decreased the mortality compared with 
      placebo (RR = 0.69; 95% CI = 0.50-0.95; P = 0.02; I (2)  = 0%). A greater 
      improvement in exercise capacity was established in patients who used coenzyme 
      Q10 than in those who used placebo (SMD = 0.62; 95% CI = 0.02-0.30; P = 0.04; I 
      (2)  = 54%). No significant difference was observed in the endpoints of left 
      heart ejection fraction between patients who received coenzyme Q10 and the 
      patients in whom placebo was administered (SMD = 0.62; 95% CI = 0.02-1.12; 
      P = 0.04; I (2)  = 75%). The two types of treatment resulted in obtaining similar 
      NYHA classification results (SMD = -0.70; 95% CI = -1.92-0.51; P = 0.26; I (2) 
       = 89%). CONCLUSION: Patients with heart failure who used coenzyme Q10 had lower 
      mortality and a higher exercise capacity improvement than the placebo-treated 
      patients with heart failure. No significant differences between the efficacy of 
      the administration of coenzyme Q10 and placebo in the endpoints of left heart 
      ejection fraction and NYHA classification were observed.
FAU - Lei, Li
AU  - Lei L
AD  - Department of Cardiology, Yulin Traditional Chinese Medicine Hospital, Yulin, 
      719000, China.
FAU - Liu, Yan
AU  - Liu Y
AUID- ORCID: 0000-0002-8444-0497
AD  - First Department of Cardiology, Yulin Second Hospital, South Wenhua Road, Yulin, 
      719000, China. 476559924@qq.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20170724
PL  - England
TA  - BMC Cardiovasc Disord
JT  - BMC cardiovascular disorders
JID - 100968539
RN  - 0 (Cardiovascular Agents)
RN  - 1339-63-5 (Ubiquinone)
RN  - EJ27X76M46 (coenzyme Q10)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cardiovascular Agents/adverse effects/*therapeutic use
MH  - Chi-Square Distribution
MH  - Exercise Tolerance/drug effects
MH  - Female
MH  - Heart Failure/diagnosis/*drug therapy/mortality/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Randomized Controlled Trials as Topic
MH  - Recovery of Function
MH  - Risk Factors
MH  - Stroke Volume/drug effects
MH  - Treatment Outcome
MH  - Ubiquinone/adverse effects/*analogs & derivatives/therapeutic use
MH  - Ventricular Function, Left/drug effects
PMC - PMC5525208
OTO - NOTNLM
OT  - Cardiac failure
OT  - Coenzyme Q10
OT  - Exercise capacity
OT  - Placebo
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: As this is a meta-analysis, ethics 
      approval and consent to participate were not required. CONSENT FOR PUBLICATION: 
      Not Applicable. COMPETING INTERESTS: All authors declare that they have no 
      competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral with 
      regard to jurisdictional claims in published maps and institutional affiliations.
EDAT- 2017/07/26 06:00
MHDA- 2018/01/09 06:00
PMCR- 2017/07/24
CRDT- 2017/07/26 06:00
PHST- 2017/05/18 00:00 [received]
PHST- 2017/07/12 00:00 [accepted]
PHST- 2017/07/26 06:00 [entrez]
PHST- 2017/07/26 06:00 [pubmed]
PHST- 2018/01/09 06:00 [medline]
PHST- 2017/07/24 00:00 [pmc-release]
AID - 10.1186/s12872-017-0628-9 [pii]
AID - 628 [pii]
AID - 10.1186/s12872-017-0628-9 [doi]
PST - epublish
SO  - BMC Cardiovasc Disord. 2017 Jul 24;17(1):196. doi: 10.1186/s12872-017-0628-9.